Lyndra Therapeutics to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference

·2-min read

WATERTOWN, Mass., November 16, 2021--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced that members of its management team will present and host one-on-one meetings at the 33rd Annual Piper Sandler Virtual Healthcare Conference taking place November 30 through December 2, 2021.

An on-demand, pre-recorded presentation will be made available on the conference website starting on Monday, November 22, 2021 at 10:00 a.m. ET.

About Lyndra Therapeutics

Lyndra Therapeutics is pioneering ultra-long-acting oral therapies, which has never been done before. The company’s novel delivery system will allow people to take medicines once a week, or even less often, instead of every day. Their breakthrough oral capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something that has the potential to fundamentally change the way people take medicine. Lyndra’s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of poor or undesirable outcomes, including central nervous system diseases, oral contraception and opioid use disorder, among others. Lyndra’s lead product candidate, weekly risperidone (LYN-005), is being developed for the treatment of people living with schizophrenia and bipolar 1 disorder. The company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH. For more information, visit the company’s website at

View source version on


Investor Contact
Christopher Brinzey
ICR Westwicke

Media Contact
Dan Boyle
(818) 209-1692

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting